Author: Vitaliy Dadalyan

With Risks on The Horizon, Sell Into Strength With Penn National Stock

It's no surprise Penn National (NASDAQ:PENN) stock has held onto its epic gains from the past few months. With its casinos coming out of lockdown, investors are still itching to wager on a rapid recovery. But, more importantly, Penn's sports wagering catalyst (its partnership with Barstool Sports) stands to move the needle, if the NFL and NBA kick off their seasons on schedule later this year.Source: Jeffrey J Coleman / Shutterstock.com Yet, have investors bought only on the headlines? You can make the argument that's the case. The company's flagship casinos face lingering challenges coming out of the pandemic. It's too early to tell how much of a game-changer sports wagering will be for the company's bottom line.With over-hyped catalysts, and underappreciated risks, Penn National is "priced for perfection." That is to say, high expectations are currently priced into shares.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSure, Penn has...

Is the Fisker Deal Good or Bad News for Nikola Stock?

On July 13, Spartan Energy Acquisition Corp. (NASDAQ:SPAQ) announced that it would acquire Fisker, a Los Angeles-based startup electric vehicle maker, in a reverse merger that values the merged entity at $2.9 billion. Nikola (NASDAQ:NKLA) also went public through a reverse merger with a SPAC. Should this latest deal be interpreted as good or bad news for Nikola stock? Click to EnlargeSource: Stephanie L Sanchez / Shutterstock.com Here's a look at both sides of the argument? The Fisker Deal is Good News for Nikola StockAlthough Nikola stock has gone sideways since Fisker and Spartan announced their tie-up July 13, the deal confirms that electric SUVs and trucks are in demand from both consumers and investors alike. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 15 Growth Stocks That Are Being Propped Up By Low Rates "In electrification, we could have played in buses or trucks, but the car...

Infectious disease specialists ask U.S. govt to ensure remdesivir supply

U.S. infectious disease specialists this week asked the federal government to "use every authority it has" to ensure adequate supplies of the antiviral drug remdesivir as the number of people infected with the novel coronavirus continues to rise. In a letter to Vice President Mike Pence and Secretary of Health and Human Services (HHS) Alex Azar, the Infectious Diseases Society of America (IDSA) expressed concern that developed countries are relying on a single manufacturer for the only antiviral so far shown to be effective against COVID-19, the disease caused by the coronavirus....